Science

Looking deeper at lung disease: BMS’ approach to pulmonology research

Why do these diseases remain so challenging for patients?

For someone living with a serious lung disease, ordinary moments can start to feel different.

Walking across a room may no longer feel automatic. Climbing stairs may require a pause halfway up. A cough may interrupt a conversation. 

What may seem routine to most can become a quiet calculation of energy, breath and uncertainty. At first, these changes may be invisible to others, even as a person begins adjusting their life around symptoms. They may avoid stairs, rethink plans or conserve energy in ways that go unnoticed. But as disease progresses, the burden becomes harder to hide. Supplemental oxygen, for example, can make a once-invisible disease more visible, adding emotional strain and stigma to the physical challenges patients may face.

The changes patients feel in daily life are outward signs of underlying disruptions in the lungs — internal damage and faulty repair processes that may be underway before the full burden of disease is clear. This lived experience is why pulmonology research must look beyond symptoms.

For Bristol Myers Squibb, advancing pulmonology research means connecting that patient experience with a clearer appreciation of the disease processes that may drive lung damage, progression and long-term impact for patients.

Looking beneath the symptoms

Breathlessness, cough and fatigue may be what patients feel most directly, but they are only one chapter in a larger disease story.

Chronic pulmonary conditions can be progressive and heterogeneous. For one patient, disease may unfold as a gradual loss of stamina; for another, disease may bring more noticeable shortness of breath, reduced ability to exercise or an increased need for oxygen. Even with the same diagnosis, the path ahead can be hard to predict, leaving patients and clinicians grappling with understanding the symptoms facing them today and what may come next.

That unpredictability raises important scientific questions. What biological or environmental disruptions set lung disease in motion? How do lung cells respond to repeated injury? What happens when normal repair processes break down? And how can inflammation and tissue remodeling contribute to damage that can be difficult or impossible to reverse?

Better understanding these changes at the cellular level can help researchers identify the disease processes most important to address – and where therapeutic intervention may have the greatest potential to make a meaningful difference for patients living with pulmonary diseases.

How is BMS applying disease biology to pulmonology research?

BMS is not approaching pulmonology as a single-disease story. Its work today is anchored in pulmonary fibrosis research, but the company is bringing a broader history of scientific experience to the field. Across its research organization, BMS has built deep expertise in understanding complex disease biology and translating that insight into meaningful progress for patients. In pulmonology, that approach means starting with an understanding of the drivers that shape disease over time and pursuing multiple scientific approaches with the potential to shift expectations for care.

The symptoms patients experience day to day are central to the challenge. To make a more durable difference in those symptoms and their impact on patients’ lives, research needs to address the underlying disease processes that drive them. The goal is to better preserve respiratory capacity, support physical function and help change the long-term trajectory of disease. That is the ambition BMS is bringing to pulmonology: applying the company’s scientific strengths to a field where continued innovation is urgently needed for patients.

How does BMS’ work in pulmonary fibrosis illustrate this approach?

Pulmonary fibrosis shows why a disease biology view of complex pulmonary disease is critical.

For people living with the condition, disease progression can mean worsening respiratory symptoms, declining lung function and a growing impact on daily life.

But fibrosis, the thickening or excessive buildup of scar tissue, is not the beginning of the story. In diseases such as idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF), fibrosis can be the result of earlier biologic changes, with effects compounding over time. These changes can include repeated epithelial injury and faulty repair, inflammation and fibroblast expansion/activation — key drivers of fibrogenesis that can contribute to progressive scarring. By studying these earlier changes, researchers can better understand what may be driving progression and where there may be opportunities to intervene further upstream, before more lasting damage takes hold.

BMS’ work in LPA₁ biology in IPF and PPF offers one example of this disease biology lens in action. LPA₁, or lysophosphatidic acid receptor 1, is part of a signaling pathway implicated in fibrotic disease processes. After more than a decade studying LPA₁ biology, BMS is advancing research on the LPA/LPA₁ pathway in IPF and PPF, reflecting how insight into the processes that contribute to fibrosis can help shape clinical development in pulmonary fibrosis.

What could the next chapter of pulmonology research look like?

For patients, lung disease can be measured in the moments it changes: the stairs avoided, the plans reconsidered, the breath that takes more effort than it used to.

But the next chapter of pulmonology research will require looking beyond the observable to the biology unfolding inside the lungs. For researchers, those moments point to a deeper responsibility: to uncover the forces that can reshape how people breathe, move, sleep, plan and live.

BMS is working to chart a new course for research in respiratory diseases, grounded in patient realities and the science behind these conditions. This work keeps patients’ daily lives at the center of scientific progress.